Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Nov 14, 2022
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Nov 10, 2022
Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Nov 10, 2022
Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Nov 08, 2022
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders Nov 08, 2022
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022 Nov 03, 2022
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia Oct 27, 2022
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Oct 06, 2022
